Loading…
Brawn Biotech (BSE 530207)₹21.90+4.04%Pharmaceuticals
Brawn Biotech is compared with the 10 closest in size in Pharmaceuticals (229 companies in the industry). It has a P/E of 6.9 against a peer median of 22.0, and ROCE of 0.0% against a peer median of 1.0%, and latest-quarter sales growth of −12.4% against a peer median of −8.8%. By market cap it is #7 of 11 in this set.
As of · Peer set: 10 closest in size in Pharmaceuticals
| Company | M-cap (₹ Cr) | P/E | ROCE % | ROE % | Debt / equity | Div. yield % | Sales (₹ Cr) | Net profit (₹ Cr) | Qtr sales growth % | Qtr profit growth % | Compare |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Beryl Drugs | 13 | 31.1 | 7.2 | 4.3 | 0.25 | 0.0 | 19 | 0 | 4.8 | 292.9 | vs BSE 530207 |
| Unjha Formulations | 13 | 26.7 | 27.7 | 20.1 | 0.00 | 0.0 | 16 | 1 | −8.8 | −57.5 | vs BSE 530207 |
| ORTIN GLOBAL | 11 | — | −32.1 | −46.0 | 0.81 | 0.0 | 0 | −1 | 262.5 | — | vs BSE 530207 |
| Dipna Pharmachem | 11 | 4.2 | 8.1 | 5.3 | 0.21 | 0.0 | 129 | 3 | −87.2 | −62.7 | vs BSE 530207 |
| Adline Chem Lab | 9 | — | −933.4 | — | — | 0.0 | 0 | −0 | — | −145.5 | vs BSE 530207 |
| Ganga Pharmaceuticals | 7 | 78.1 | 2.9 | 1.3 | 0.13 | 0.0 | 3 | 0 | 9.8 | 40.0 | vs BSE 530207 |
| Brawn Biotech | 7 | 6.9 | 0.0 | 24.5 | 0.00 | 0.0 | 17 | 1 | −12.4 | — | — |
| Vivanza Biosciences | 6 | 14.5 | 6.0 | 9.4 | 2.33 | 0.0 | 116 | 0 | 3.9 | 75.0 | vs BSE 530207 |
| Decipher Labs | 6 | — | −16.6 | −14.2 | 0.02 | 0.0 | 14 | −3 | −16.8 | — | vs BSE 530207 |
| MPS Pharmaa | 4 | — | −13.1 | −176.9 | 107.04 | 0.0 | 0 | −1 | — | — | vs BSE 530207 |
| Shyama Computronics and Services | 4 | 22.0 | 1.0 | 1.1 | 0.00 | 0.0 | 0 | 0 | −16.7 | −70.0 | vs BSE 530207 |
| Peer median | 7 | 22.0 | 1.0 | 2.8 | 0.17 | 0.0 | 14 | 0 | −8.8 | −57.5 |
Listed companies closest to Brawn Biotech in Pharmaceuticals include Beryl Drugs, Unjha Formulations, ORTIN GLOBAL, Dipna Pharmachem, Adline Chem Lab, Ganga Pharmaceuticals, Vivanza Biosciences, Decipher Labs.
Beryl Drugs, with a market cap of ₹13.00 Cr.
Brawn Biotech trades at a P/E of 6.9; the median of its peer set is 22.0. A P/E above or below the median is a description, not a judgement on value.
Brawn Biotech's return on capital employed is 0.0%, below the peer median of 1.0%.